Cognoa Licenses Innovative Digital Therapeutic Technology.

PALO ALTO, Calif., April 10, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has exclusively licensed technology from the Stanford University School of Medicine to accelerate development and worldwide commercialization of a novel digital therapeutic for children with autism spectrum disorder (ASD). Underscoring the need for earlier access to personalized…

MedTechDive logo

Cognoa’s autism devices win breakthrough status.

FDA has granted breakthrough designations to Cognoa’s digital autism diagnostic and therapeutic devices, the company announced Wednesday. The devices are designed to enable physicians to diagnose autism spectrum disorder (ASD) earlier and improve the social skills and responsiveness of children with the condition. Read full article here.


Cognoa Receives FDA Breakthrough Designations for Autism Diagnostic and Digital Therapeutic Devices.

PALO ALTO, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has received Breakthrough Device designations from the U.S. Food and Drug Administration (FDA) for its lead products, the first digital diagnostic and digital therapeutic devices for autism. These products are the foundation of  Cognoa’s precision health platform…


Cognoa Selected by Cambia Health Solutions to Provide Support for Employees Raising Young Children.

Email Print Friendly ShareJanuary 08, 2019 09:03 ET | Source: Cognoa PALO ALTO, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) — Cognoa, a digital behavioral health company, announced today that Cambia Health Solutions, Inc. (Cambia) is incorporating Cognoa’s evidence-based platform within its subsidiary health plans. Cognoa provides support for employees caring for children older than one. Cognoa offers reliable guidance on day-to-day challenges and personalized resources that enable…


Cognoa Demonstrates Advances of its AI-Based Technology for Identifying Autism in Children

PALO ALTO, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) — Cognoa, a digital behavioral health company, today announces results from a clinical study of its second-generation AI based algorithms which demonstrates accuracy improvements over its first-generation screening algorithm in supporting the diagnosis of autism spectrum disorder (ASD) in young children. Published in Journal of the American Medical Informatics Association, the data provides…

MobiHealthNews logo

Studies of autism screening app highlight machine learning’s capacity to iterate, improve.

In May, a pair of studies were published in the journals Autism Research and the Journal of the American Medical Informatics Association (JAMIA) that evaluated Cognoa’s artificial intelligence-based tool for early identification of autism in children. While both investigations suggest that the tool’s performance significantly exceeded those of other standardized screeners. Read full article here.